DanDi Bioscience

ENG

다국어페이지

ENG
KOR

DanDi Bioscience

KOR

NEWS

What’s new?

HOME
PR
NEWS
- Notice

No.	Title	Date
32	HLB Science, xxxselected for excellence in healthcare R&D in 2022	2023-01-13
31	HLB Science announces preclinical results of sepsis treatment	2023-01-13
30	HLB Science, Sepsis Treatment France Phase 1 Clinical IND Approval	2023-01-13
29	HLB Science, 2022 KONEX science and technology innovation company relay IR held	2023-01-13
28	HLB Science applies for phase 1 IND for sepsis treatment in France	2023-01-13
27	Youngmin Park, CEO of HLB Science, “Submitted European clinical plan for sepsis treatment in June”	2023-01-13
26	HLB Science, xxxselected by Shinhan Investment Corp.	2023-01-13
25	Dandi Bioscience changed to HLB Science, new articles of incorporation for issuance of exchangeable	2023-01-13
24	Dandi Bioscience, Dandibio “Entering domestic phase 1 trial for endotoxin-targeted Alzheimer’s disea	2023-01-13
23	Dandi Bioscience, “Applying for European phase 1 sepsis treatment next month”	2023-01-13

1
2
3
4
5

DanDi Bioscience

CEO of HLB Science Inc. : Jong-Sun Yoon Business license number : 677-88-00337 Ethical Management(Cyber Report)

CopyrightⓒHLB Science. ALL RIGHTS RESERVED